ArticleCardio-oncology (London, England)2025
Risk of myocardial infarction following capecitabine treatment in patients with gastrointestinal cancer - a nationwide registry-based study.
Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fluoropyrimidine-induced cardiotoxicity: outcomes and safety of chemotherapy reintroduction in a retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyocardial infarction (MI) is an adverse event potentially associated with capecitabine treatment, potentially impacting the continuation of cancer therapy. However, data on its incidence remain limited.
methodsUsing Danish nationwide registries, we identified patients with gastrointestinal (GI) cancer treated with capecitabine (2004–2016) and compared them to age- and sex-matched controls without cancer. Patients with prior ischemic heart disease were excluded but were subsequently analyzed as a separate secondary cohort. Cumulative incidences of MI and competing risks were calculated, and multivariable regression analyses were performed.
resultsA total of 23,820 patients with GI cancer treated with capecitabine and 47,640 controls without cancer were included. Differences in comorbidities and antianginal medications were not significantly different (P > 0.05 for all). At 6 months, the cumulative incidence of MI was significantly higher for patients treated with capecitabine at 0.6% (95% CI: 0.5%-0.7%) versus 0.3% (95% CI: 0.3%-0.4%) in controls, with a competing risk of death of 15.2% versus 0.7%. At 1 year, the cumulative incidence of MI for patients receiving capecitabine was 0.7% (95% CI: 0.6%-0.9%) versus 0.6% (95% CI: 0.5%-0.6%) among controls, with a competing risk for death of 29.7% versus 1.6%. After accounting for competing risks, the sub distribution hazard ratios indicated an increased risk of MI for patients receiving capecitabine compared with control subjects at both 6 months (hazard ratio: 2.02; 95% CI: 1.57–2.60; P < 0.001) and 12 months (hazard ratio: 1.28; 95% CI: 1.05–1.57; P = 0.015).
conclusionCapecitabine treatment in GI cancer patients was associated with an increased MI risk at 6 and 12 months compared to controls, though absolute risks were low. Given the high competing mortality, the clinical relevance of this increased MI risk appears limited. In a secondary analysis of patients with known ischemic heart disease, our findings suggest that cardiovascular risk assessment and monitoring is warranted during capecitabine therapy, rather than routine avoidance of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.